MedPlus To Sell Over 500 Off-Patent Drugs At Huge Discounts

Hyderabad : MedPlus Health Services, which runs a chain of pharmacies, said it will be selling 500 off-patent therapeutic and chronic medicines under its own brand with a discount of 50-80 per cent.

Announcing this at a press conference on Wednesday, G Madhukar Reddy, managing director and chief executive officer, MedPlus, said the company tied up with multiple reputed pharmaceutical manufacturing companies to produce high quality off-patent medicines that enables the firm to pass on the benefit to the consumer.

“MedPlus will initially offer discounts on over 500 therapeutic and chronic medicines and will eventually extend discounts on more than 800 products in the next three months,” Reddy said.

These medicines will include over-the-counter (OTC) and prescription drugs used in treating various diseases such as hypertension, diabetes and kidney ailments, he said.

The 500 products currently being offered cover about 53 per cent of the therapeutic segments and the products will be sold under the MedPlus brand, he added.

Currently, it operates about 3,800 stores and has plans to add another 800 new pharmacies during 2023-24.  “Our size allows us to eliminate marketing, distribution and other retail costs and will pass on the benefits to customers,” he said.

  • Related Posts

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn bio sciences Inc, a leading patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Queen’s University to develop and manufacture AAV9-GM2, a gene therapy…

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    Cellution Biologics Inc, a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

    Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

    Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad

    Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad